Human T-cell Lymphotropic Virus Type-1-associated Bronchioloalveolar Disorder with Non-necrotizing Granulomas: A Case Report and Literature Review
Intern Med. 2023 Sep 1. doi: 10.2169/internalmedicine.2201-23. Online ahead of print.ABSTRACTHuman T-cell lymphotropic virus type-1 (HTLV-1)-associated bronchioloalveolar disorder (HABA) is a pulmonary disorder characterized by lymphocytic infiltration of the peribronchiolar space and interstitium in HTLV-1 carriers and in adult T-cell leukemia/lymphoma (ATLL). We herein report an 85-year-old woman carrying HTLV-1 with HABA who presented with a miliary pattern of micronodules in both lungs on high-resolution computed tomography and a lymphocytic infiltrate with non-necrotizing granulomas on pathology. This rare case of HAB...
Source: Internal Medicine - September 4, 2023 Category: Internal Medicine Authors: Satomi Kimura Yukihiro Umeda Ryoko Egashira Kazuhiro Tabata Akifumi Muramoto Mihoko Morita Makiko Yamaguchi Yuko Waseda Yoshiaki Imamura Takahiro Yamauchi Tamotsu Ishizuka Source Type: research

A child with polyarthritis and chronic lung disease: a case report of ataxia-telangiectasia
ConclusionsAlthough rare, A-T should always be ruled out in case of pulmonary bronchiectasis and gait disturbances even in the absence of bulbar or skin telangiectasia. Autoimmune and granulomatous disorders must to be considered as differential diagnosis.
Source: Italian Journal of Pediatrics - September 4, 2023 Category: Pediatrics Source Type: research

Fibrotic Pulmonary Sarcoidosis
Fibrotic pulmonary sarcoidosis (fPS) affects about 20% of patients. fPS carries a significant morbidity and mortality. However, its prognosis is highly variable, depending mainly on fibrosis extent, functional impairment severity, and the development of pulmonary hypertension. Moreover, fPS outcomes are also influenced by several other complications, including acute exacerbations, and infections. fPS natural history is unknown, in particular regarding the risk of progressive self-sustaining fibrosis. The management of fPS is challenging, including anti-inflammatory treatment if granulomatous activity persists, rehabilitati...
Source: Clinics in Chest Medicine - September 4, 2023 Category: Respiratory Medicine Authors: Hilario Nunes, Pierre-Yves Brillet, Jean-Fran çois Bernaudin, Thomas Gille, Dominique Valeyre, Florence Jeny Source Type: research

Hematologic and Oncologic Aspects of Sarcoidosis
The hematologic system is frequently involved in sarcoidosis. Lymphopenia is the most common hematologic manifestation noted, although anemia and thrombocytopenia also occur. The etiology of these common manifestations can be direct granulomatous infiltration of bone marrow, lymph nodes, or spleen or related to immunologic dysfunction. Although not life threatening, these problems can lead to cytopenias requiring close monitoring in patients receiving a variety of disease treatments. The relationship between sarcoidosis and malignancy remains complex. However, some sarcoidosis patients are at increased risk for the develop...
Source: Clinics in Chest Medicine - September 4, 2023 Category: Respiratory Medicine Authors: Elyse E. Lower, Robert P. Baughman Source Type: research

Cardiac Sarcoidosis
Cardiac involvement is a major cause of morbidity and mortality in patients with sarcoidosis. It is important to distinguish between clinical manifest diseases from clinically silent diseases. Advanced cardiac imaging studies are crucial in the diagnostic pathway. In suspected isolated cardiac sarcoidosis, it ’s key to rule out alternative diagnoses. Therapeutic options can be divided into immunosuppressive agents, guideline-directed medical therapy, antiarrhythmic medications, device/ablation therapy, and heart transplantation.
Source: Clinics in Chest Medicine - September 4, 2023 Category: Respiratory Medicine Authors: Manuel L. Ribeiro Neto, Christine L. Jellis, Paul C. Cremer, Logan J. Harper, Ziad Taimeh, Daniel A. Culver Source Type: research

Neurosarcoidosis and Neurologic Complications of Sarcoidosis Treatment
Sarcoidosis is an immune-mediated multisystem granulomatous disorder. Neurosarcoidosis (NS) accounts for 5% to 35% of cases. The diagnostic evaluation of NS can be a clinical challenge. Gadolinium-enhanced magnetic resonance imaging (MRI) is the gold standard to evaluate central nervous system NS. In almost all cases treatment is warranted. Although glucocorticoids remain the first-line therapy in patients with sarcoidosis, in NS timely initiation of second- or third-line treatment is strongly recommended. Of these, tumor necrosis factor-alpha inhibitors are the most promising. However, the treatment itself may be responsi...
Source: Clinics in Chest Medicine - September 4, 2023 Category: Respiratory Medicine Authors: Mareye Voortman, Marjolein Drent, Barney J. Stern Source Type: research

Monitoring of Sarcoidosis
This article focuses on the monitoring of pulmonary sarcoidosis. The monitoring of sarcoidosis is, in part, focused on serial change in major organ involvement but also includes diagnostic re-evaluation and review of change in quality of life. Recent criteria for progression of fibrotic interstitial lung disease are adapted to pulmonary sarcoidosis. The frequency and nature of monitoring are discussed, integrating baseline risk stratification and strategic treatment goals. Individual variables used to identify changes in pulmonary disease severity are discussed with a focus on their flaws and the need for a multidimensiona...
Source: Clinics in Chest Medicine - September 2, 2023 Category: Respiratory Medicine Authors: Vasileios Kouranos, Athol Umfrey Wells Source Type: research

Health-Related Quality of Life Assessment in Sarcoidosis
Health-related quality of life (HRQoL) is of major concern to patients with sarcoidosis. HRQoL impairment is the most common reason to treat the disease. Advances in patient-reported outcome (PRO) methodology offer the promise to use these instruments to follow quality of life in individual patients with sarcoidosis over time. Several HRQoL issues will be highlighted including their clinical importance, common causes in patients with sarcoidosis, the construction and use of PROs in clinical sarcoidosis trials, methods to adapt PROs to monitor HRQoL in individual patients with sarcoidosis, and the approach to improving HRQoL in this disease.
Source: Clinics in Chest Medicine - September 1, 2023 Category: Respiratory Medicine Authors: Marc A. Judson Source Type: research

Sarcoidosis-Associated Pulmonary Hypertension
Pulmonary hypertension is a life-threatening complication of advanced sarcoidosis. Many mechanisms can cause an elevation of pulmonary pressure in sarcoidosis, leading to precapillary or postcapillary pulmonary hypertension. Sarcoidosis-associated pulmonary hypertension contributes to severe exertional dyspnea, reduced exercise capacity, and notably compromised the survival. Despite the critical functional and prognostic implications of pulmonary hypertension in sarcoidosis, there is a scarcity of specific guidelines on the management of these patients due to a lack of evidence. Hence, further research is required to ident...
Source: Clinics in Chest Medicine - September 1, 2023 Category: Respiratory Medicine Authors: Laurent Savale, Peter Dorfm üller, Athénaïs Boucly, Xavier Jaïs, Thomas Lacoste-Palasset, Mitja Jevnikar, Andrei Seferian, Marc Humbert, Olivier Sitbon, David Montani Source Type: research

Ocular Sarcoidosis
Sarcoidosis frequently affects the eye and can do so in many different ways. Sarcoidosis causing uveitis can have distinctive features that facilitate identifying sarcoidosis as the cause of the uveitis. Progress is being made in elucidating ocular sarcoidosis, as for example, by transcriptomics, genetics, therapy, and imaging.
Source: Clinics in Chest Medicine - September 1, 2023 Category: Respiratory Medicine Authors: James T. Rosenbaum, Sirichai Pasadhika Source Type: research

Identification of Environmental Exposures Associated with Risk of Sarcoidosis in African Americans
Annals of the American Thoracic Society,Volume 20, Issue 9, Page 1274-1282, September 2023.
Source: Annals of the American Thoracic Society - September 1, 2023 Category: Respiratory Medicine Authors: Albert M. Levin Ruicong She Yalei Chen Indra Adrianto Indrani Datta Ian M. Loveless Lori Garman Courtney G. Montgomery Jia Li Michael C. Iannuzzi Benjamin A. Rybicki Source Type: research

Sarcoidosis masquerading as hair-dye induced allergic contact dermatitis
Gopikrishnan Anjaneyan, Nandhetha G Sreenivaasan, Lekshmi Sajini, CB Mithun, Asmita A MehtaIndian Journal of Dermatology 2023 68(4):489-489
Source: Indian Journal of Dermatology - August 31, 2023 Category: Dermatology Authors: Gopikrishnan Anjaneyan Nandhetha G Sreenivaasan Lekshmi Sajini CB Mithun Asmita A Mehta Source Type: research

Peripheral Airway Sarcoidosis: Seeing What Was Previously Invisible
Am J Respir Crit Care Med. 2023 Aug 29. doi: 10.1164/rccm.202304-0781IM. Online ahead of print.NO ABSTRACTPMID:37642604 | DOI:10.1164/rccm.202304-0781IM
Source: American Journal of Respiratory and Critical Care Medicine - August 29, 2023 Category: Respiratory Medicine Authors: Rocco Trisolini Giuliana Pasciuto Alessandra Cancellieri Chiara Agros ì Daniele Magnini Luca Richeldi Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20